Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Gemcitabine transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma

Lookup NU author(s): John Hammond

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Background/Aims: Transcatheter arterial chemoembolization (TACE) has been shown to increase survival in patients with unresectable hepatocellular carcinoma (HCC), however toxicity from commonly used agents limits its use in unresectable disease. Gemcitabine is a well tolerated chemotherapeutic agent with a high first pass clearance. In this study we evaluated a cohort of patients with unresectable HCC treated with gemcitabine-TACE alone. Methodology: A review of all patients that underwent gemcitabine-TACE for unresectable HCC from 2002 to 2006 was performed. No patients were eligible for resection, liver transplantation or ablation. All patients received gemcitabine-TACE alone. The primary outcome measure was survival from first treatment. Secondary outcome measures included radiological response and toxicity. Results: 55 patients underwent a total of 172 gemcitabine-TACE treatments for unresectable HCC. Median age was 64.7 years. All patients had Barcelona-Clinic Liver Cancer (BCLC) stage B (44%) or C (56%) disease. Median survival following gemcitabine-TACE was 8.8 months. 22% demonstrated a partial response and 61% had stable disease. 6% experienced grade 3/4 adverse events. There was 1 treatment related death. Conclusion: Gemcitabine-TACE is well tolerated and appears to provide an alternative agent for patients with unresectable HCC undergoing chemoembolization. © H.G.E. Update Medical Publishing S.A.

Publication metadata

Author(s): Hammond JS, Franko J, Holloway SE, Heckman JT, Orons PD, Gamblin TC

Publication type: Article

Publication status: Published

Journal: Hepato-Gastroenterology

Year: 2014

Volume: 61

Issue: 133

Pages: 1339-1343

Online publication date: 01/07/2014

Acceptance date: 02/04/2014

ISSN (electronic): 0172-6390

Publisher: H.G.E. Update Medical Publishing Ltd.

URL: https://doi.org/10.5754/hge12720

DOI: 10.5754/hge12720

PubMed id: 25436307

Altmetrics

Altmetrics provided by Altmetric

Share